-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 10th, Arctic Vision, an ophthalmic biotechnology company in the clinical development stage focusing on innovative therapies, announced today that it has completed a Series B financing of more than US$100 million.
This round of financing was led by Zhengxingu Capital.
JiMu’s current pipeline includes 3 phase 3 products introduced in the clinical phase, namely ARVN001 (Fengmai®) for the treatment of uveitis macular edema, ARVN002 for the treatment of progressive myopia in children, and ARVN003 for the treatment of presbyopia .